ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol Myers faces $6.4bn lawsuit over cancer drug delay
June 07, 2021UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR) -
BMS faces lawsuit from Celgene shareholders over missed deadline for Breyanzi approval
June 04, 2021Celgene's former shareholders sued Bristol Myers Squibb in US court on Thursday claiming that the drugmaker failed to use its best efforts to secure FDA approval of Breyanzi (lisocabtagene maraleucel) by the end of 2020 -
BMS to invest in new cell therapy manufacturing site in Europe
April 26, 2021Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands. -
Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy
March 31, 2021Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and R/R ... -
FDA Approves BMS CAR-T Cell Therapy
February 10, 2021Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma. -
FDA approves third gene therapy for large B-cell lymphoma
February 09, 2021Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
Pharma Sources Insight January 2025
